임상 면역분석기 시장 : 유형별, 용도별, 최종사용자별 - 세계 기회 분석 및 산업 예측(2024-2033년)

Clinical Immunoanalyzer Market By Type , By Application By End user : Global Opportunity Analysis and Industry Forecast, 2024-2033

US $ 4,425 ￦ 6,049,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 7,412 ￦ 10,132,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

임상 면역분석기 시장은 2023년 47억 달러로 평가되며, 2024-2033년 연평균 5.5% 성장하여 2033년에는 80억 달러에 달할 것으로 예상됩니다.

임상 면역분석기는 환자 시료에서 항체, 항원 및 기타 면역계 성분과 같은 다양한 면역학적 마커를 정량적, 정성적으로 분석하기 위해 의료 실험실에서 사용되는 진단 기기입니다. 임상 면역분석기는 정확하고 빠른 결과를 제공함으로써 임상 현장에서 질병 진단, 면역 반응 모니터링, 치료 방침 결정에 중요한 역할을 합니다. 이러한 분석기는 검사 결과를 신속하게 제공하기 때문에 적시에 진단 및 치료 방침을 결정하는 데 필수적입니다.

임상 면역분석기 세계 시장 성장은 암, 자가면역질환, 감염성 질환과 같은 만성질환의 심각한 유병률 증가와 조기 및 정확한 진단에 대한 중요성 증가에 의해 주도되고 있습니다. 조사에 따르면, 전 세계 인구의 약 20%가 당뇨병, 심혈관질환 등 만성질환을 앓고 있어 정기적인 모니터링과 진단이 필요한 것으로 나타났습니다. 이에 따라 관련 바이오마커를 효율적으로 검출할 수 있는 임상 면역분석 장비에 대한 수요가 증가하고 있습니다. 또한, 노인 인구의 급격한 증가는 세계 시장의 주요 원동력이 되고 있습니다. 노인들이 다양한 질병에 걸리기 쉽기 때문에 고급 진단 솔루션의 필요성이 높아지고 있기 때문입니다. 세계보건기구(WHO)에 따르면 2019년 60세 이상 노인 인구는 10억 명에 달합니다. 이 숫자는 2030년까지 14억 명, 2050년까지 21억 명으로 증가할 것으로 추정됩니다. 노인 인구의 증가에 따라 만성질환의 유병률은 크게 증가할 것으로 예상됩니다. 또한 건강 및 예방 의료에 대한 인식이 높아짐에 따라 더 나은 건강 관리를 위한 첨단 진단 도구의 사용이 촉진되어 시장 성장을 촉진하고 있습니다. 제조업체들은 실험실 워크플로우를 간소화하고 인적 오류를 줄이며 처리량을 높이기 위해 면역분석기 자동화에 주력하고 있습니다. 또한 AI와 ML을 면역분석기에 통합하여 데이터 해석을 강화하고, 프로세스를 자동화하고, 진단 정확도를 향상시키고 있습니다. 이러한 추세는 첨단 진단기기의 도입률 향상에 크게 기여하고 있습니다. 그러나 첨단 면역분석기의 높은 초기 투자 및 유지보수 비용, 정기적인 유지보수, 교정 및 기술 지원의 필요성이 시장 성장을 저해하는 요인으로 작용하고 있습니다. 또한, 많은 국가에서 국민들의 요구를 충족시킬 수 있는 적절한 의료 시설이 부족하고 접근성이 제한적이라는 점도 시장 성장을 저해하는 주요 요인으로 작용하고 있습니다. 반면, 바이오마커를 보다 정확하고 신뢰성 있게 검출할 수 있는 고감도 및 고특이성 분석 기술의 발전은 예측 기간 동안 세계 시장 확대에 유리한 기회를 제공할 것으로 예상됩니다. 또한, 신흥국 시장의 의료 인프라 개발은 이들 지역에서 임상 면역분석기기의 채택을 촉진하고 시장 규모를 확대하는 데 기여하고 있습니다.

세계 임상 면역분석기 산업은 유형, 용도, 최종사용자 및 지역으로 분류됩니다. 유형별로 시장은 ELISA, CLIA, RIA 및 기타로 분류됩니다. 응용 분야는 임상 화학, 내분비, 종양, 감염 진단, 순환기 및 기타로 분류됩니다. 최종사용자에 따라 병원 및 클리닉, 진단 실험실, 연구기관, 기타로 세분화됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다.

주요 조사 결과

유형별로는 ELISA 부문이 2024-2033년 사이 시장을 장악할 것으로 예상됩니다.

용도별로는 감염성 질환 진단이 예측 기간 동안 주요 부문으로 부상할 것으로 예상됩니다.

병원 및 클리닉 부문은 향후 몇 년 동안 임상 면역분석기의 주요 최종사용자로 작용할 것으로 예상됩니다.

지역별로 보면 임상 면역분석기 시장은 가까운 장래에 북미 전역에서 큰 성장을 이룰 가능성이 높습니다.

이 보고서는 사용자 정의가 가능합니다.

• 규제 가이드라인
• 고객의 관심사에 따른 추가 기업 개요
• 평균 판매가격 분석/가격대 분석
• 기업 개요 확대 목록
• 상환 시나리오

목차

제1장 소개

제2장 주요 요약

제3장 시장 상황

• 시장 정의와 범위
• 주요 조사 결과
  • 주요 투자 기회
  • 주요 성공 전략
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 임상 면역분석기 시장 : 유형별

• 시장 개요
• ELISA
• CLIA
• RIA
• 기타

제5장 임상 면역분석기 시장 : 용도별

• 시장 개요
• 임상화학
• 내분비학
• 종양학
• 감염증 진단
• 순환기
• 기타

제6장 임상 면역분석기 시장 : 최종사용자별

• 시장 개요
• 병원과 클리닉
• 진단 실험실
• 연구기관
• 기타

제7장 임상 면역분석기 시장 : 지역별

• 시장 개요
• 북미
  • 주요 시장 동향과 기회
  • 미국의 임상 면역분석기 시장
  • 캐나다의 임상 면역분석기 시장
  • 멕시코의 임상 면역분석기 시장
• 유럽
  • 주요 시장 동향과 기회
  • 프랑스의 임상 면역분석기 시장
  • 독일의 임상 면역분석기 시장
  • 이탈리아의 임상 면역분석기 시장
  • 스페인의 임상 면역분석기 시장
  • 영국의 임상 면역분석기 시장
  • 기타 유럽의 임상 면역분석기 시장
• 아시아태평양
  • 주요 시장 동향과 기회
  • 중국의 임상 면역분석기 시장
  • 일본의 임상 면역분석기 시장
  • 인도의 임상 면역분석기 시장
  • 한국의 임상 면역분석기 시장
  • 호주의 임상 면역분석기 시장
  • 기타 아시아태평양의 임상 면역분석기 시장
• 라틴아메리카, 중동 및 아프리카
  • 주요 시장 동향과 기회
  • 브라질의 임상 면역분석기 시장
  • 남아프리카공화국의 임상 면역분석기 시장
  • 사우디아라비아의 임상 면역분석기 시장
  • 기타 라틴아메리카, 중동 및 아프리카의 임상 면역분석기 시장

제8장 경쟁 상황

• 소개
• 주요 성공 전략
• 주요 10개 기업 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2023년)

제9장 기업 개요

• Roche Diagnostics Corporation
• Abbott
• Siemens AG.
• Beckman Coulter
• Ortho-Clinical Diagnostics
• Bio-Rad
• BioMerieux
• DiaSorin S.p.A.
• Werfen Life
• Thermo Fisher Scientific

ksm

영문 목차

영문목차

The clinical immunoanalyzer market was valued at $4.7 billion in 2023, and is projected to reach $8.0 billion by 2033, growing at a CAGR of 5.5% from 2024 to 2033.

Clinical immunoanalyzer is a diagnostic instrument used in medical laboratories to perform quantitative and qualitative analyses of various immunological markers such as antibodies, antigens, and other immune system components in patient samples. By providing accurate and rapid results, clinical immunoanalyzers play a critical role in diagnosing diseases, monitoring immune responses, and guiding treatment decisions in clinical settings. These analyzers deliver quick turnaround times for test results, which is crucial for timely diagnosis and treatment decisions.

The growth of the global clinical immunoanalyzer market is driven by alarming rise in prevalence of chronic conditions such as cancer, autoimmune diseases, and infectious diseases and increase in emphasis on early and precise diagnosis. Studies have shown that approximately 20% of the global population suffers from chronic diseases such as diabetes and cardiovascular disorders, which require regular monitoring and diagnostics. This drives the demand for clinical immunoanalyzers capable of efficiently detecting relevant biomarkers. Furthermore, surge in geriatric population acts as the key driving force of the global market. This is attributed to the fact that aged individuals are highly susceptible to various diseases, which fosters the need for advanced diagnostic solutions. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. With increasing aged population, the incidence of chronic conditions is expected to rise significantly. Moreover, increase in awareness about health and preventive care promotes the use of advanced diagnostic tools for better health management, which augments the market growth. Manufacturers are focusing on automation of immunoanalyzers to streamline laboratory workflows, reduce human error, and increase throughput as well as integration of AI and ML into immunoanalyzers to enhance data interpretation, automate processes, and improve diagnostic accuracy. These trends are notably contributing to higher adoption rates of advanced diagnostic equipment. However, high initial investment and maintenance costs of advanced immunoanalyzers and need for regular maintenance, calibration, and technical support restrain the market growth. Moreover, lack of appropriate health facilities to meet population needs in most countries and limited access act as the key deterrent factors of the market. On the contrary, ongoing improvements in assay technologies are leading to higher sensitivity and specificity to enable more accurate and reliable detection of biomarker are expected to offer lucrative opportunities for expansion of the global market during the forecast period. Furthermore, development of healthcare infrastructure in emerging markets is driving the adoption of clinical immunoanalyzers in these regions, expanding market reach.

The global clinical immunoanalyzer industry is segmented into type, application, end user, and region. On the basis of type, the market is categorized into ELISA, CLIA, RIA, and others. Depending on application, it is categorized into clinical chemistry, endocrinology, oncology, infectious disease diagnostics, cardiology, and others. By end user, it is fragmented into hospitals & clinics, diagnostic laboratories, research institutes, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the ELISA segment is expected to dominate the market from 2024 to 2033.

On the basis of application, infectious disease diagnostics is anticipated to emerge as the leading segment during the forecast period.

The hospitals & clinics segment is projected to serve as the major end user of clinical immunoanalyzers in the coming years.

Region wise, the clinical immunoanalyzer market is likely to experience significant growth across North America in the near future.

Competition Analysis

Competitive analysis and profiles of the major players in the global clinical immunoanalyzer market include Roche Diagnostics Corporation, Abbott, Siemens AG., Beckman Coulter, Ortho-Clinical Diagnostics, Bio-Rad, bioMerieux, DiaSorin S.p.A., Werfen Life, and Thermo Fisher Scientific. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and strengthen their foothold in the global market.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Average Selling Price Analysis / Price Point Analysis
• Expanded list for Company Profiles
• Reimbursement Scenario

Key Market Segments

By Type

• ELISA
• CLIA
• RIA
• Others

By Application

• Clinical Chemistry
• Endocrinology
• Oncology
• Infectious Disease Diagnostics
• Cardiology
• Others

By End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Research Institutes
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA

Key Market Players:

• Roche Diagnostics Corporation
• Abbott
• Siemens AG.
• Beckman Coulter
• Ortho-Clinical Diagnostics
• Bio-Rad
• bioMerieux
• DiaSorin S.p.A.
• Werfen Life
• Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report Description
• 1.2. Key Market Segments
• 1.3. Key Benefits
• 1.4. Research Methodology
  • 1.4.1. Primary Research
  • 1.4.2. Secondary Research
  • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

• 3.1. Market Definition and Scope
• 3.2. Key Findings
  • 3.2.1. Top Investment Pockets
  • 3.2.2. Top Winning Strategies
• 3.3. Porter's Five Forces Analysis
  • 3.3.1. Bargaining Power of Suppliers
  • 3.3.2. Threat of New Entrants
  • 3.3.3. Threat of Substitutes
  • 3.3.4. Competitive Rivalry
  • 3.3.5. Bargaining Power among Buyers
• 3.4. Market Dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: CLINICAL IMMUNOANALYZER MARKET, BY TYPE

• 4.1. Market Overview
  • 4.1.1 Market Size and Forecast, By Type
• 4.2. ELISA
  • 4.2.1. Key Market Trends, Growth Factors and Opportunities
  • 4.2.2. Market Size and Forecast, By Region
  • 4.2.3. Market Share Analysis, By Country
• 4.3. CLIA
  • 4.3.1. Key Market Trends, Growth Factors and Opportunities
  • 4.3.2. Market Size and Forecast, By Region
  • 4.3.3. Market Share Analysis, By Country
• 4.4. RIA
  • 4.4.1. Key Market Trends, Growth Factors and Opportunities
  • 4.4.2. Market Size and Forecast, By Region
  • 4.4.3. Market Share Analysis, By Country
• 4.5. Others
  • 4.5.1. Key Market Trends, Growth Factors and Opportunities
  • 4.5.2. Market Size and Forecast, By Region
  • 4.5.3. Market Share Analysis, By Country

CHAPTER 5: CLINICAL IMMUNOANALYZER MARKET, BY APPLICATION

• 5.1. Market Overview
  • 5.1.1 Market Size and Forecast, By Application
• 5.2. Clinical Chemistry
  • 5.2.1. Key Market Trends, Growth Factors and Opportunities
  • 5.2.2. Market Size and Forecast, By Region
  • 5.2.3. Market Share Analysis, By Country
• 5.3. Endocrinology
  • 5.3.1. Key Market Trends, Growth Factors and Opportunities
  • 5.3.2. Market Size and Forecast, By Region
  • 5.3.3. Market Share Analysis, By Country
• 5.4. Oncology
  • 5.4.1. Key Market Trends, Growth Factors and Opportunities
  • 5.4.2. Market Size and Forecast, By Region
  • 5.4.3. Market Share Analysis, By Country
• 5.5. Infectious Disease Diagnostics
  • 5.5.1. Key Market Trends, Growth Factors and Opportunities
  • 5.5.2. Market Size and Forecast, By Region
  • 5.5.3. Market Share Analysis, By Country
• 5.6. Cardiology
  • 5.6.1. Key Market Trends, Growth Factors and Opportunities
  • 5.6.2. Market Size and Forecast, By Region
  • 5.6.3. Market Share Analysis, By Country
• 5.7. Others
  • 5.7.1. Key Market Trends, Growth Factors and Opportunities
  • 5.7.2. Market Size and Forecast, By Region
  • 5.7.3. Market Share Analysis, By Country

CHAPTER 6: CLINICAL IMMUNOANALYZER MARKET, BY END USER

• 6.1. Market Overview
  • 6.1.1 Market Size and Forecast, By End User
• 6.2. Hospitals And Clinics
  • 6.2.1. Key Market Trends, Growth Factors and Opportunities
  • 6.2.2. Market Size and Forecast, By Region
  • 6.2.3. Market Share Analysis, By Country
• 6.3. Diagnostic Laboratories
  • 6.3.1. Key Market Trends, Growth Factors and Opportunities
  • 6.3.2. Market Size and Forecast, By Region
  • 6.3.3. Market Share Analysis, By Country
• 6.4. Research Institutes
  • 6.4.1. Key Market Trends, Growth Factors and Opportunities
  • 6.4.2. Market Size and Forecast, By Region
  • 6.4.3. Market Share Analysis, By Country
• 6.5. Others
  • 6.5.1. Key Market Trends, Growth Factors and Opportunities
  • 6.5.2. Market Size and Forecast, By Region
  • 6.5.3. Market Share Analysis, By Country

CHAPTER 7: CLINICAL IMMUNOANALYZER MARKET, BY REGION

• 7.1. Market Overview
  • 7.1.1 Market Size and Forecast, By Region
• 7.2. North America
  • 7.2.1. Key Market Trends and Opportunities
  • 7.2.2. Market Size and Forecast, By Type
  • 7.2.3. Market Size and Forecast, By Application
  • 7.2.4. Market Size and Forecast, By End User
  • 7.2.5. Market Size and Forecast, By Country
  • 7.2.6. U.S. Clinical Immunoanalyzer Market
    • 7.2.6.1. Market Size and Forecast, By Type
    • 7.2.6.2. Market Size and Forecast, By Application
    • 7.2.6.3. Market Size and Forecast, By End User
  • 7.2.7. Canada Clinical Immunoanalyzer Market
    • 7.2.7.1. Market Size and Forecast, By Type
    • 7.2.7.2. Market Size and Forecast, By Application
    • 7.2.7.3. Market Size and Forecast, By End User
  • 7.2.8. Mexico Clinical Immunoanalyzer Market
    • 7.2.8.1. Market Size and Forecast, By Type
    • 7.2.8.2. Market Size and Forecast, By Application
    • 7.2.8.3. Market Size and Forecast, By End User
• 7.3. Europe
  • 7.3.1. Key Market Trends and Opportunities
  • 7.3.2. Market Size and Forecast, By Type
  • 7.3.3. Market Size and Forecast, By Application
  • 7.3.4. Market Size and Forecast, By End User
  • 7.3.5. Market Size and Forecast, By Country
  • 7.3.6. France Clinical Immunoanalyzer Market
    • 7.3.6.1. Market Size and Forecast, By Type
    • 7.3.6.2. Market Size and Forecast, By Application
    • 7.3.6.3. Market Size and Forecast, By End User
  • 7.3.7. Germany Clinical Immunoanalyzer Market
    • 7.3.7.1. Market Size and Forecast, By Type
    • 7.3.7.2. Market Size and Forecast, By Application
    • 7.3.7.3. Market Size and Forecast, By End User
  • 7.3.8. Italy Clinical Immunoanalyzer Market
    • 7.3.8.1. Market Size and Forecast, By Type
    • 7.3.8.2. Market Size and Forecast, By Application
    • 7.3.8.3. Market Size and Forecast, By End User
  • 7.3.9. Spain Clinical Immunoanalyzer Market
    • 7.3.9.1. Market Size and Forecast, By Type
    • 7.3.9.2. Market Size and Forecast, By Application
    • 7.3.9.3. Market Size and Forecast, By End User
  • 7.3.10. UK Clinical Immunoanalyzer Market
    • 7.3.10.1. Market Size and Forecast, By Type
    • 7.3.10.2. Market Size and Forecast, By Application
    • 7.3.10.3. Market Size and Forecast, By End User
  • 7.3.11. Rest of Europe Clinical Immunoanalyzer Market
    • 7.3.11.1. Market Size and Forecast, By Type
    • 7.3.11.2. Market Size and Forecast, By Application
    • 7.3.11.3. Market Size and Forecast, By End User
• 7.4. Asia-Pacific
  • 7.4.1. Key Market Trends and Opportunities
  • 7.4.2. Market Size and Forecast, By Type
  • 7.4.3. Market Size and Forecast, By Application
  • 7.4.4. Market Size and Forecast, By End User
  • 7.4.5. Market Size and Forecast, By Country
  • 7.4.6. China Clinical Immunoanalyzer Market
    • 7.4.6.1. Market Size and Forecast, By Type
    • 7.4.6.2. Market Size and Forecast, By Application
    • 7.4.6.3. Market Size and Forecast, By End User
  • 7.4.7. Japan Clinical Immunoanalyzer Market
    • 7.4.7.1. Market Size and Forecast, By Type
    • 7.4.7.2. Market Size and Forecast, By Application
    • 7.4.7.3. Market Size and Forecast, By End User
  • 7.4.8. India Clinical Immunoanalyzer Market
    • 7.4.8.1. Market Size and Forecast, By Type
    • 7.4.8.2. Market Size and Forecast, By Application
    • 7.4.8.3. Market Size and Forecast, By End User
  • 7.4.9. South Korea Clinical Immunoanalyzer Market
    • 7.4.9.1. Market Size and Forecast, By Type
    • 7.4.9.2. Market Size and Forecast, By Application
    • 7.4.9.3. Market Size and Forecast, By End User
  • 7.4.10. Australia Clinical Immunoanalyzer Market
    • 7.4.10.1. Market Size and Forecast, By Type
    • 7.4.10.2. Market Size and Forecast, By Application
    • 7.4.10.3. Market Size and Forecast, By End User
  • 7.4.11. Rest of Asia-Pacific Clinical Immunoanalyzer Market
    • 7.4.11.1. Market Size and Forecast, By Type
    • 7.4.11.2. Market Size and Forecast, By Application
    • 7.4.11.3. Market Size and Forecast, By End User
• 7.5. LAMEA
  • 7.5.1. Key Market Trends and Opportunities
  • 7.5.2. Market Size and Forecast, By Type
  • 7.5.3. Market Size and Forecast, By Application
  • 7.5.4. Market Size and Forecast, By End User
  • 7.5.5. Market Size and Forecast, By Country
  • 7.5.6. Brazil Clinical Immunoanalyzer Market
    • 7.5.6.1. Market Size and Forecast, By Type
    • 7.5.6.2. Market Size and Forecast, By Application
    • 7.5.6.3. Market Size and Forecast, By End User
  • 7.5.7. South Africa Clinical Immunoanalyzer Market
    • 7.5.7.1. Market Size and Forecast, By Type
    • 7.5.7.2. Market Size and Forecast, By Application
    • 7.5.7.3. Market Size and Forecast, By End User
  • 7.5.8. Saudi Arabia Clinical Immunoanalyzer Market
    • 7.5.8.1. Market Size and Forecast, By Type
    • 7.5.8.2. Market Size and Forecast, By Application
    • 7.5.8.3. Market Size and Forecast, By End User
  • 7.5.9. Rest of LAMEA Clinical Immunoanalyzer Market
    • 7.5.9.1. Market Size and Forecast, By Type
    • 7.5.9.2. Market Size and Forecast, By Application
    • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top Winning Strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

• 9.1. Roche Diagnostics Corporation
  • 9.1.1. Company Overview
  • 9.1.2. Key Executives
  • 9.1.3. Company Snapshot
  • 9.1.4. Operating Business Segments
  • 9.1.5. Product Portfolio
  • 9.1.6. Business Performance
  • 9.1.7. Key Strategic Moves and Developments
• 9.2. Abbott
  • 9.2.1. Company Overview
  • 9.2.2. Key Executives
  • 9.2.3. Company Snapshot
  • 9.2.4. Operating Business Segments
  • 9.2.5. Product Portfolio
  • 9.2.6. Business Performance
  • 9.2.7. Key Strategic Moves and Developments
• 9.3. Siemens AG.
  • 9.3.1. Company Overview
  • 9.3.2. Key Executives
  • 9.3.3. Company Snapshot
  • 9.3.4. Operating Business Segments
  • 9.3.5. Product Portfolio
  • 9.3.6. Business Performance
  • 9.3.7. Key Strategic Moves and Developments
• 9.4. Beckman Coulter
  • 9.4.1. Company Overview
  • 9.4.2. Key Executives
  • 9.4.3. Company Snapshot
  • 9.4.4. Operating Business Segments
  • 9.4.5. Product Portfolio
  • 9.4.6. Business Performance
  • 9.4.7. Key Strategic Moves and Developments
• 9.5. Ortho-Clinical Diagnostics
  • 9.5.1. Company Overview
  • 9.5.2. Key Executives
  • 9.5.3. Company Snapshot
  • 9.5.4. Operating Business Segments
  • 9.5.5. Product Portfolio
  • 9.5.6. Business Performance
  • 9.5.7. Key Strategic Moves and Developments
• 9.6. Bio-Rad
  • 9.6.1. Company Overview
  • 9.6.2. Key Executives
  • 9.6.3. Company Snapshot
  • 9.6.4. Operating Business Segments
  • 9.6.5. Product Portfolio
  • 9.6.6. Business Performance
  • 9.6.7. Key Strategic Moves and Developments
• 9.7. BioMerieux
  • 9.7.1. Company Overview
  • 9.7.2. Key Executives
  • 9.7.3. Company Snapshot
  • 9.7.4. Operating Business Segments
  • 9.7.5. Product Portfolio
  • 9.7.6. Business Performance
  • 9.7.7. Key Strategic Moves and Developments
• 9.8. DiaSorin S.p.A.
  • 9.8.1. Company Overview
  • 9.8.2. Key Executives
  • 9.8.3. Company Snapshot
  • 9.8.4. Operating Business Segments
  • 9.8.5. Product Portfolio
  • 9.8.6. Business Performance
  • 9.8.7. Key Strategic Moves and Developments
• 9.9. Werfen Life
  • 9.9.1. Company Overview
  • 9.9.2. Key Executives
  • 9.9.3. Company Snapshot
  • 9.9.4. Operating Business Segments
  • 9.9.5. Product Portfolio
  • 9.9.6. Business Performance
  • 9.9.7. Key Strategic Moves and Developments
• 9.10. Thermo Fisher Scientific
  • 9.10.1. Company Overview
  • 9.10.2. Key Executives
  • 9.10.3. Company Snapshot
  • 9.10.4. Operating Business Segments
  • 9.10.5. Product Portfolio
  • 9.10.6. Business Performance
  • 9.10.7. Key Strategic Moves and Developments

관련자료